Episode Details

Former Nebraska Senator Ben Sasse, diagnosed with metastatic pancreatic cancer, joined a clinical trial for daraxonrasib, a pill from Revolution Medicines. This targeted therapy, which targets the RAS gene switch fueling most pancreatic tumors, has shown promising results, doubling median survival to thirteen months in phase three trials. Sasse reported a significant drop in tumor size and less pain after starting the treatment. Experts hail it as a game-changer and the first targeted therapy of its kind, offering real progress in the fight against this brutal cancer. While it comes with side effects, early combos with chemo show even better tumor shrinkage and more patients thriving at six months. Sasse sees it as a miracle alongside his faith, urging reflection on life. Trials are now testing it upfront, which could reshape care for this tough fight.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/4a3cb6cf5d62b92b